Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1
NCT02251457Phase 1Completed
- Sponsor
- The Ohio State University
- Start
- Aug 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ranolazine in myotonia congenita (MC), paramyotonia congenita (PMC) and myotonic dystrophy type 1 (DM1), sponsored by The Ohio State University. Primary endpoints: Short Form Health Survey at 1 month, Individualized Neuromuscular Quality of Life Questionnaire at 1 month and 2 more. Started Aug 2014; status: completed.
02
Drugs
ranolazine
03
Conditions
myotonia congenita (MC)paramyotonia congenita (PMC)myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT02251457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251457.